Stryker stock trades at EUR 277.90, up 0.23% premarket
Published on 11/04/2026 at 08:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOutlook Reset Shapes Premarket Focus
- Stryker reported third-quarter sales growth of 7.7% and adjusted earnings per share growth of 10.3%.
- Management reduced its full-year 2026 organic sales growth outlook to 6.5% to 7.0%.
- MedSurg and Neurotechnology grew faster than Orthopaedics in the third quarter.
Stryker stock traded at EUR 277.90 on Lang & Schwarz at 08:38 CET on Wednesday, November 4, 2026, 0.23 percent above the Xetra close of Tuesday, November 3, 2026 at EUR 277.25.
Investors can follow the real-time quote of Stryker stock as the market digests the company's latest outlook.
Outlook Reset Shapes Premarket Focus
In its third-quarter release, Stryker reported net sales of USD 6.52 billion, up 7.7 percent from a year earlier. Adjusted earnings per share rose 10.3 percent to USD 3.52, while reported net earnings fell 12.3 percent to USD 753 million. The reported result included a USD 293 million goodwill impairment.
MedSurg and Neurotechnology sales increased 9.2 percent, compared with 5.7 percent growth in Orthopaedics. Stryker now expects full-year organic sales growth of 6.5 percent to 7.0 percent and adjusted earnings per share of USD 14.80 to USD 14.90. The company had previously forecast organic growth of 8.3 percent to 9.3 percent, according to the release.
The broader market backdrop is covered in current market reports.
